ATEZOLIZUMAB FOR THE TREATMENT OF NON-SMALL CELL LUNG CANCER: UPDATED OVERALL SURVIVAL ANALYSIS FROM IMPOWER110

Abstract

Atezolizumab is a programmed death protein ligand 1 (PD-1) inhibitor, approved for the first-line advanced or metastatic non-small cell lung cancer (NSCLC) monotherapy when tumor expresses a high programmed death-ligand 1 (PDL1) level (≥ 50 %), with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumor aberrations. IMpower110 previously revealed significant overall survival (OS) benefits with atezolizumab versus platinum-based chemotherapy for NSCLC patients with high PD-L1 expression. We present the final OS analysis in lower PD L1 expression groups and updated exploratory analysis in the high PD-L1 expression group.